79 results on '"Palmore TN"'
Search Results
2. Testing the tube: Assessing silver as a potential 'silver bullet' for preventing ventilator-associated pneumonia.
- Author
-
Palmore TN and Henderson DK
- Published
- 2010
- Full Text
- View/download PDF
3. A retrospective chart review assessing antibiotic treatment of hospitalized patients with discordant Clostridioides difficile assays in an urban hospitalized setting.
- Author
-
Stoddart C, Kuo I, Spence MA, and Palmore TN
- Abstract
Clostridioides difficile infection (CDI) threatens vulnerable populations in health care. Two-step testing improves specificity, avoiding over-treatment. This study analyzed inpatient records to estimate diagnostic outcomes and identify characteristics associated with treatment after discordant testing. Among discordant patients, those aged 65+ years were significantly more likely to be prescribed antibiotics (67% vs 39%)., Competing Interests: The authors declare none., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
4. For Patient Safety, It Is Not Time to Take Off Masks in Health Care Settings.
- Author
-
Palmore TN and Henderson DK
- Subjects
- Humans, SARS-CoV-2, Delivery of Health Care, Patient Safety, COVID-19 prevention & control
- Abstract
Competing Interests: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-1190.
- Published
- 2023
- Full Text
- View/download PDF
5. Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination.
- Author
-
Cohen JI, Dropulic L, Wang K, Gangler K, Morgan K, Liepshutz K, Krogmann T, Ali MA, Qin J, Wang J, Vogel JS, Lei Y, Suzuki-Williams LP, Spalding C, Palmore TN, and Burbelo PD
- Subjects
- Humans, Antibodies, Viral, COVID-19 Vaccines, Vaccination, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Background: Most studies of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) measure antibody or cellular responses in blood; however, the virus infects mucosal surfaces in the nose and conjunctivae and infectious virus is rarely if ever present in the blood., Methods: We used luciferase immunoprecipitation assays to measure SARS-CoV-2 antibody levels in the plasma, nose, and saliva of infected persons and vaccine recipients. These assays measure antibody that can precipitate the SAR-CoV-2 spike and nucleocapsid proteins., Results: Levels of plasma anti-spike antibody declined less rapidly than levels of anti-nucleocapsid antibody in infected persons. SARS-CoV-2 anti-spike antibody levels in the nose declined more rapidly than antibody levels in the blood after vaccination of infected persons. Vaccination of previously infected persons boosted anti-spike antibody in plasma more than in the nose or saliva. Nasal and saliva anti-spike antibody levels were significantly correlated with plasma antibody in infected persons who had not been vaccinated and after vaccination of uninfected persons., Conclusions: Persistently elevated SARS-CoV-2 antibody in plasma may not indicate persistence of antibody at mucosal sites such as the nose. The strong correlation of SARS-CoV-2 antibody in the nose and saliva with that in the blood suggests that mucosal antibodies are derived primarily from transudation from the blood rather than local production. While SARS-CoV-2 vaccine given peripherally boosted mucosal immune responses in infected persons, the increase in antibody titers was higher in plasma than at mucosal sites. Taken together, these observations indicate the need for development of mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs., Clinical Trials Registration: NCT01306084., Competing Interests: Potential conflicts of interest. K. W. holds stock in Moderna and Pfizer. T. N. P. reports grant support to her university from AbbVie (human immunodeficiency virus [HIV]), Finch Therapeutics (Clostridioides difficile), Rigel (fostamatinib), and Gilead (HIV); payment for chapters on COVID infection control and monkeypox in UpToDate; and roles as a member of the IDWeek Program Planning Committee and as councillor on the Society for Healthcare Epidemiology of America’s Board of Trustees. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2023
- Full Text
- View/download PDF
6. Genomic analysis, immunomodulation and deep phenotyping of patients with nodding syndrome.
- Author
-
Soldatos A, Nutman TB, Johnson T, Dowell SF, Sejvar JJ, Wilson MR, DeRisi JL, Inati SK, Groden C, Evans C, O'Connell EM, Toliva BO, Aceng JR, Aryek-Kwe J, Toro C, Stratakis CA, Buckler AG, Cantilena C, Palmore TN, Thurm A, Baker EH, Chang R, Fauni H, Adams D, Macnamara EF, Lau CC, Malicdan MCV, Pusey-Swerdzewski B, Downing R, Bunga S, Thomas JD, Gahl WA, and Nath A
- Subjects
- United States, Humans, Cohort Studies, Immunomodulation, Genomics, Nodding Syndrome, Onchocerciasis
- Abstract
The aetiology of nodding syndrome remains unclear, and comprehensive genotyping and phenotyping data from patients remain sparse. Our objectives were to characterize the phenotype of patients with nodding syndrome, investigate potential contributors to disease aetiology, and evaluate response to immunotherapy. This cohort study investigated members of a single-family unit from Lamwo District, Uganda. The participants for this study were selected by the Ugandan Ministry of Health as representative for nodding syndrome and with a conducive family structure for genomic analyses. Of the eight family members who participated in the study at the National Institutes of Health (NIH) Clinical Center, three had nodding syndrome. The three affected patients were extensively evaluated with metagenomic sequencing for infectious pathogens, exome sequencing, spinal fluid immune analyses, neurometabolic and toxicology testing, continuous electroencephalography and neuroimaging. Five unaffected family members underwent a subset of testing for comparison. A distinctive interictal pattern of sleep-activated bursts of generalized and multifocal epileptiform discharges and slowing was observed in two patients. Brain imaging showed two patients had mild generalized cerebral atrophy, and both patients and unaffected family members had excessive metal deposition in the basal ganglia. Trace metal biochemical evaluation was normal. CSF was non-inflammatory and one patient had CSF-restricted oligoclonal bands. Onchocerca volvulus-specific antibodies were present in all patients and skin snips were negative for active onchocerciasis. Metagenomic sequencing of serum and CSF revealed hepatitis B virus in the serum of one patient. Vitamin B6 metabolites were borderline low in all family members and CSF pyridoxine metabolites were normal. Mitochondrial DNA testing was normal. Exome sequencing did not identify potentially causal candidate gene variants. Nodding syndrome is characterized by a distinctive pattern of sleep-activated epileptiform activity. The associated growth stunting may be due to hypothalamic dysfunction. Extensive testing years after disease onset did not clarify a causal aetiology. A trial of immunomodulation (plasmapheresis in two patients and intravenous immunoglobulin in one patient) was given without short-term effect, but longer-term follow-up was not possible to fully assess any benefit of this intervention., (Published by Oxford University Press on behalf of the Guarantors of Brain 2022.)
- Published
- 2023
- Full Text
- View/download PDF
7. Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations.
- Author
-
Talbot TR, Hayden MK, Yokoe DS, Malani AN, Amer HA, Kalu IC, Logan LK, Moehring RW, Munoz-Price S, Palmore TN, Weber DJ, and Wright SB
- Subjects
- Humans, Respiratory Aerosols and Droplets, Health Facilities, Infection Control methods, SARS-CoV-2, COVID-19 diagnosis, COVID-19 prevention & control
- Abstract
Testing of asymptomatic patients for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) (ie, "asymptomatic screening) to attempt to reduce the risk of nosocomial transmission has been extensive and resource intensive, and such testing is of unclear benefit when added to other layers of infection prevention mitigation controls. In addition, the logistic challenges and costs related to screening program implementation, data noting the lack of substantial aerosol generation with elective controlled intubation, extubation, and other procedures, and the adverse patient and facility consequences of asymptomatic screening call into question the utility of this infection prevention intervention. Consequently, the Society for Healthcare Epidemiology of America (SHEA) recommends against routine universal use of asymptomatic screening for SARS-CoV-2 in healthcare facilities. Specifically, preprocedure asymptomatic screening is unlikely to provide incremental benefit in preventing SARS-CoV-2 transmission in the procedural and perioperative environment when other infection prevention strategies are in place, and it should not be considered a requirement for all patients. Admission screening may be beneficial during times of increased virus transmission in some settings where other layers of controls are limited (eg, behavioral health, congregate care, or shared patient rooms), but widespread routine use of admission asymptomatic screening is not recommended over strengthening other infection prevention controls. In this commentary, we outline the challenges surrounding the use of asymptomatic screening, including logistics and costs of implementing a screening program, and adverse patient and facility consequences. We review data pertaining to the lack of substantial aerosol generation during elective controlled intubation, extubation, and other procedures, and we provide guidance for when asymptomatic screening for SARS-CoV-2 may be considered in a limited scope.
- Published
- 2023
- Full Text
- View/download PDF
8. Sharp decline in rates of community respiratory viral detection among patients at the National Institutes of Health Clinical Center during the coronavirus disease 2019 (COVID-19) pandemic.
- Author
-
Woolbert ME, Spalding CD, Sinaii N, Decker BK, Palmore TN, and Henderson DK
- Subjects
- Humans, Pandemics, Retrospective Studies, COVID-19 diagnosis, COVID-19 epidemiology, Respiratory Tract Infections diagnosis, Respiratory Tract Infections epidemiology, Viruses, Influenza, Human epidemiology
- Abstract
Objectives: To analyze the frequency and rates of community respiratory virus infections detected in patients at the National Institutes of Health Clinical Center (NIHCC) between January 2015 and March 2021, comparing the trends before and during the coronavirus disease 2019 (COVID-19) pandemic., Methods: We conducted a retrospective study comparing frequency and rates of community respiratory viruses detected in NIHCC patients between January 2015 and March 2021. Test results from nasopharyngeal swabs and washes, bronchoalveolar lavages, and bronchial washes were included in this study. Results from viral-challenge studies and repeated positives were excluded. A quantitative data analysis was completed using cross tabulations. Comparisons were performed using mixed models, applying the Dunnett correction for multiplicity., Results: Frequency of all respiratory pathogens declined from an annual range of 0.88%-1.97% between January 2015 and March 2020 to 0.29% between April 2020 and March 2021. Individual viral pathogens declined sharply in frequency during the same period, with no cases of influenza A/B orparainfluenza and 1 case of respiratory syncytial virus (RSV). Rhino/enterovirusdetection continued, but with a substantially lower frequency of 4.27% between April 2020 and March 2021, compared with an annual range of 8.65%-18.28% between January 2015 and March 2020., Conclusions: The decrease in viral respiratory infections detected in NIHCC patients during the pandemic was likely due to the layered COVID-19 prevention and mitigation measures implemented in the community and the hospital. Hospitals should consider continuing the use of nonpharmaceutical interventions in the future to prevent nosocomial transmission of respiratory viruses during times of high community viral load.
- Published
- 2023
- Full Text
- View/download PDF
9. Monkeypox Virus-Associated Severe Proctitis Treated With Oral Tecovirimat: A Report of Two Cases.
- Author
-
Lucar J, Roberts A, Saardi KM, Yee R, Siegel MO, and Palmore TN
- Subjects
- Humans, Monkeypox virus, Isoindoles, Mpox, Monkeypox, Proctitis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
10. Experience with voluntary severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing of asymptomatic staff at the National Institutes of Health for one year.
- Author
-
Totten AH, Matlock AM, Bailin H, Revoir J, Siwy CM, Joyce M, Coffey P, Henderson DK, Palmore TN, Frank KM, and McKeeby J
- Subjects
- United States, Humans, COVID-19 Testing, Clinical Laboratory Techniques, National Institutes of Health (U.S.), SARS-CoV-2, COVID-19 diagnosis
- Abstract
Voluntary asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing was provided by the NIH Clinical Center over 1 year. Among 105,927 tests, 0.2% were positive. Among eligible staff, 79% participated with variable frequency and 61% of positive individuals had symptoms at the time of testing. Saliva specimen collection was chosen as an option less frequently than midturbinate collection.
- Published
- 2022
- Full Text
- View/download PDF
11. Web Exclusive. Annals On Call - Diagnosis and Treatment of Monkeypox Proctitis.
- Author
-
Centor RM, Lucar J, and Palmore TN
- Published
- 2022
- Full Text
- View/download PDF
12. Adding New Fuel to the Fire: Monkeypox in the Time of COVID-19-Implications for Health Care Personnel.
- Author
-
Palmore TN and Henderson DK
- Subjects
- Conservation of Natural Resources, Delivery of Health Care, Health Personnel, Humans, COVID-19, Mpox, Monkeypox
- Published
- 2022
- Full Text
- View/download PDF
13. Management of healthcare personnel living with hepatitis B, hepatitis C, or human immunodeficiency virus in US healthcare institutions.
- Author
-
Henderson DK, Dembry LM, Sifri CD, Palmore TN, Dellinger EP, Yokoe DS, Grady C, Heller T, Weber D, Del Rio C, Fishman NO, Deloney VM, Lundstrom T, and Babcock HM
- Subjects
- Delivery of Health Care, HIV, Health Personnel, Hepacivirus, Hepatitis B virus, Humans, HIV Infections epidemiology, Hepatitis B epidemiology, Hepatitis B prevention & control, Hepatitis C epidemiology
- Published
- 2022
- Full Text
- View/download PDF
14. Preventing Transmission of Respiratory Viruses in the Health Care Setting.
- Author
-
Palmore TN and Henderson DK
- Subjects
- Delivery of Health Care, Humans, Respiratory Tract Infections, Viruses
- Published
- 2021
- Full Text
- View/download PDF
15. Healthcare-associated infections during the coronavirus disease 2019 (COVID-19) pandemic.
- Author
-
Palmore TN and Henderson DK
- Subjects
- Delivery of Health Care, Humans, Pandemics, SARS-CoV-2, COVID-19, Cross Infection epidemiology
- Published
- 2021
- Full Text
- View/download PDF
16. Detection of SARS-CoV2 variants by Mesa Accula.
- Author
-
Totten AH, Youn JH, Roder A, Ghedin E, Palmore TN, Frank KM, Das S, and Zelazny AM
- Subjects
- Humans, SARS-CoV-2, COVID-19
- Published
- 2021
- Full Text
- View/download PDF
17. Pooled Saliva Specimens for SARS-CoV-2 Testing.
- Author
-
Barat B, Das S, De Giorgi V, Henderson DK, Kopka S, Lau AF, Miller T, Moriarty T, Palmore TN, Sawney S, Spalding C, Tanjutco P, Wortmann G, Zelazny AM, and Frank KM
- Subjects
- Humans, Nasopharynx, Reverse Transcriptase Polymerase Chain Reaction, Specimen Handling methods, COVID-19 diagnosis, COVID-19 Nucleic Acid Testing methods, Mass Screening methods, SARS-CoV-2 isolation & purification, Saliva virology
- Abstract
We evaluated saliva (SAL) specimens for SARS-CoV-2 reverse transcriptase PCR (RT-PCR) testing by comparison of 459 prospectively paired nasopharyngeal (NP) or midturbinate (MT) swabs from 449 individuals with the aim of using saliva for asymptomatic screening. Samples were collected in a drive-through car line for symptomatic individuals ( n = 380) and in the emergency department (ED) ( n = 69). The percentages of positive and negative agreement of saliva compared to nasopharyngeal swab were 81.1% (95% confidence interval [CI], 65.8% to 90.5%) and 99.8% (95% CI, 98.7% to 100%), respectively. The percent positive agreement increased to 90.0% (95% CI, 74.4% to 96.5%) when considering only samples with moderate to high viral load (cycle threshold [ C
T ] for the NP, ≤34). Pools of five saliva specimens were also evaluated on three platforms, bioMérieux NucliSENS easyMAG with ABI 7500Fast (CDC assay), Hologic Panther Fusion, and Roche Cobas 6800. The average loss of signal upon pooling was 2 to 3 CT values across the platforms. The sensitivities of detecting a positive specimen in a pool compared with testing individually were 94%, 90%, and 94% for the CDC 2019-nCoV real-time RT-PCR, Panther Fusion SARS-CoV-2 assay, and Cobas SARS-CoV-2 test, respectively, with decreased sample detection trending with lower viral load. We conclude that although pooled saliva testing, as collected in this study, is not quite as sensitive as NP/MT testing, saliva testing is adequate to detect individuals with higher viral loads in an asymptomatic screening program, does not require swabs or viral transport medium for collection, and may help to improve voluntary screening compliance for those individuals averse to various forms of nasal collections.- Published
- 2021
- Full Text
- View/download PDF
18. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.
- Author
-
Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, Klompas M, Hooper DC, Powers JH 3rd, Srinivasan A, Danner RL, and Adjemian J
- Subjects
- Aged, Aged, 80 and over, Anti-Bacterial Agents administration & dosage, Cohort Studies, Drug Resistance, Bacterial, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Sepsis mortality, United States, Anti-Bacterial Agents therapeutic use, Hospitals, Inappropriate Prescribing, Sepsis drug therapy, Sepsis microbiology
- Abstract
Background: The prevalence and effects of inappropriate empirical antibiotic therapy for bloodstream infections are unclear. We aimed to establish the population-level burden, predictors, and mortality risk of in-vitro susceptibility-discordant empirical antibiotic therapy among patients with bloodstream infections., Methods: Our retrospective cohort analysis of electronic health record data from 131 hospitals in the USA included patients with suspected-and subsequently confirmed-bloodstream infections who were treated empirically with systemic antibiotics between Jan 1, 2005, and Dec 31, 2014. We included all patients with monomicrobial bacteraemia caused by common bloodstream pathogens who received at least one systemic antibiotic either on the day blood cultures were drawn or the day after, and for whom susceptibility data were available. We calculated the prevalence of discordant empirical antibiotic therapy-which was defined as receiving antibiotics on the day blood culture samples were drawn to which the cultured isolate was not susceptible in vitro-overall and by hospital type by using regression tree analysis. We used generalised estimating equations to identify predictors of receiving discordant empirical antibiotic therapy, and used logistic regression to calculate adjusted odds ratios for the relationship between in-hospital mortality and discordant empirical antibiotic therapy., Findings: 21 608 patients with bloodstream infections received empirical antibiotic therapy on the day of first blood culture collection. Of these patients, 4165 (19%) received discordant empirical antibiotic therapy. Discordant empirical antibiotic therapy was independently associated with increased risk of mortality (adjusted odds ratio 1·46 [95% CI, 1·28-1·66]; p<0·0001), a relationship that was unaffected by the presence or absence of resistance or sepsis or septic shock. Infection with antibiotic-resistant species strongly predicted receiving discordant empirical therapy (adjusted odds ratio 9·09 [95% CI 7·68-10·76]; p<0·0001). Most incidences of discordant empirical antibiotic therapy and associated deaths occurred among patients with bloodstream infections caused by Staphylococcus aureus or Enterobacterales., Interpretation: Approximately one in five patients with bloodstream infections in US hospitals received discordant empirical antibiotic therapy, receipt of which was closely associated with infection with antibiotic-resistant pathogens. Receiving discordant empirical antibiotic therapy was associated with increased odds of mortality overall, even in patients without sepsis. Early identification of bloodstream pathogens and resistance will probably improve population-level outcomes., Funding: US National Institutes of Health, US Centers for Disease Control and Prevention, and US Agency for Healthcare Research and Quality., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Institutional quality and patient safety programs: An overview for the healthcare epidemiologist.
- Author
-
Sreeramoju PV, Palmore TN, Lee GM, Edmond MB, Patterson JE, Sepkowitz KA, Goldmann DA, Henderson DK, and Kaye KS
- Subjects
- Delivery of Health Care, Health Facilities, Humans, Quality of Health Care, Epidemiologists, Patient Safety
- Published
- 2021
- Full Text
- View/download PDF
20. Pooled Saliva Specimens for SARS-CoV-2 Testing.
- Author
-
Barat B, Das S, De Giorgi V, Henderson DK, Kopka S, Lau AF, Miller T, Moriarty T, Palmore TN, Sawney S, Spalding C, Tanjutco P, Wortmann G, Zelazny AM, and Frank KM
- Abstract
We evaluated saliva (SAL) specimens for SARS-CoV-2 RT-PCR testing by comparison of 459 prospectively paired nasopharyngeal (NP) or mid-turbinate (MT) swabs from 449 individuals with the aim of using saliva for asymptomatic screening. Samples were collected in a drive-through car line for symptomatic individuals (N=380) and in the emergency department (ED) (N=69). The percent positive and negative agreement of saliva compared to nasopharyngeal swab were 81.1% (95% CI: 65.8% - 90.5%) and 99.8% (95% CI: 98.7% - 100%), respectively. The sensitivity increased to 90.0% (95% CI: 74.4% - 96.5%) when considering only samples with moderate to high viral load (Cycle threshold (Ct) for the NP <=34). Pools of five saliva specimens were also evaluated on three platforms: bioMérieux NucliSENS easyMAG with ABI 7500Fast (CDC assay), Hologic Panther Fusion, and Roche COBAS 6800. The median loss of signal upon pooling was 2-4 Ct values across the platforms. The sensitivity of detecting a positive specimen in a pool compared with testing individually was 100%, 93%, and 95% for CDC 2019-nCoV Real-Time RT-PCR, Panther Fusion® SARS-CoV-2 assay, and cobas® SARS-CoV-2 test respectively, with decreased sample detection trending with lower viral load. We conclude that although pooled saliva testing, as collected in this study, is not quite as sensitive as NP/MT testing, saliva testing is adequate to detect individuals with higher viral loads in an asymptomatic screening program, does not require swabs or viral transport media for collection, and may help to improve voluntary screening compliance for those individuals averse to various forms of nasal collections.
- Published
- 2020
- Full Text
- View/download PDF
21. Aging and haptic shape discrimination: the effects of variations in size.
- Author
-
Norman JF, Dukes JM, and Palmore TN
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Discrimination, Psychological, Humans, Young Adult, Aging, Form Perception, Size Perception, Visual Perception
- Abstract
Seventy-two older and younger adults haptically discriminated the solid shape of natural objects (bell peppers, Capsicum annuum). Plastic copies of the original-sized fruits were used as experimental stimuli, as well as copies that were reduced in size to 1/8th and 1/27th of the original object volumes. If haptic object shape is represented in a part-based manner, then haptic shape discrimination performance should be at least partly size invariant, since changes only in scale do not affect an object's constituent parts. On any given trial, participants sequentially explored two bell pepper replicas and were required to judge whether they possessed the same shape or had different shapes. For some participants, the objects to be discriminated possessed the same size, while for others, the two objects had different sizes. It was found that variations in scale did significantly reduce the participants' haptic sensitivities to shape. Nevertheless, the discrimination performance obtained for large variations in size was no lower than that obtained for smaller variations in size. The results also demonstrated that increases in age modestly affect haptic shape discrimination performance: the d' values of the older participants were 15.5% lower than those of the younger participants.
- Published
- 2020
- Full Text
- View/download PDF
22. Plasmid Dissemination and Selection of a Multidrug-Resistant Klebsiella pneumoniae Strain during Transplant-Associated Antibiotic Therapy.
- Author
-
Conlan S, Lau AF, Deming C, Spalding CD, Lee-Lin S, Thomas PJ, Park M, Dekker JP, Frank KM, Palmore TN, and Segre JA
- Subjects
- Antibiotic Prophylaxis methods, Hematopoietic Stem Cell Transplantation, Humans, Klebsiella pneumoniae isolation & purification, Selection, Genetic, Transplant Recipients, Anti-Bacterial Agents administration & dosage, Drug Resistance, Multiple, Bacterial, Gene Transfer, Horizontal, Klebsiella Infections microbiology, Klebsiella pneumoniae drug effects, Plasmids analysis
- Abstract
Antibiotics, which are used both to prevent and to treat infections, are a mainstay therapy for lifesaving procedures such as transplantation. For this reason, and many others, increased antibiotic resistance among human-associated pathogens, such as the carbapenem-resistant Enterobacteriaceae species, is of grave concern. In this study, we report on a hematopoietic stem cell transplant recipient in whom cultures detected the emergence of carbapenem resistance and spread across five strains of bacteria that persisted for over a year. Carbapenem resistance in Citrobacter freundii , Enterobacter cloacae , Klebsiella aerogenes , and Klebsiella pneumoniae was linked to a pair of plasmids, each carrying the Klebsiella pneumoniae carbapenemase gene ( bla
KPC ). Surveillance cultures identified a carbapenem-susceptible strain of Citrobacter freundii that may have become resistant through horizontal gene transfer of these plasmids. Selection of a multidrug-resistant Klebsiella pneumoniae strain was also detected following combination antibiotic therapy. Here we report a plasmid carrying the blaKPC gene with broad host range that poses the additional threat of spreading to endogenous members of the human gut microbiome. IMPORTANCE Antibiotic-resistant bacteria are a serious threat to medically fragile patient populations. The spread of antibiotic resistance through plasmid-mediated mechanisms is of grave concern as it can lead to the conversion of endogenous patient-associated strains to difficult-to-treat pathogens., (Copyright © 2019 Conlan et al.)- Published
- 2019
- Full Text
- View/download PDF
23. A retrospective cohort study of antibiotic exposure and vancomycin-resistant Enterococcus recolonization.
- Author
-
Hughes HY, Odom RT, Michelin AV, Snitkin ES, Sinaii N, Milstone AM, Henderson DK, and Palmore TN
- Subjects
- Adult, Aged, Cohort Studies, Cross Infection drug therapy, Enterococcus faecium, Female, Humans, Leukemia complications, Lymphoproliferative Disorders complications, Male, Middle Aged, National Institutes of Health (U.S.), Retrospective Studies, Risk Factors, United States epidemiology, Vancomycin-Resistant Enterococci, Young Adult, Anti-Bacterial Agents therapeutic use, Cross Infection epidemiology, Cross Infection microbiology, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections epidemiology
- Abstract
Objective: In the National Institutes of Health (NIH) Clinical Center, patients colonized or infected with vancomycin-resistant Enterococcus (VRE) are placed in contact isolation until they are deemed "decolonized," defined as having 3 consecutive perirectal swabs negative for VRE. Some decolonized patients later develop recurrent growth of VRE from surveillance or clinical cultures (ie, "recolonized"), although that finding may represent recrudescence or new acquisition of VRE. We describe the dynamics of VRE colonization and infection and their relationship to receipt of antibiotics., Methods: In this retrospective cohort study of patients at the National Institutes of Health Clinical Center, baseline characteristics were collected via chart review. Antibiotic exposure and hospital days were calculated as proportions of VRE decolonized days. Using survival analysis, we assessed the relationship between antibiotic exposure and time to VRE recolonization in a subcohort analysis of 72 decolonized patients., Results: In total, 350 patients were either colonized or infected with VRE. Among polymerase chain reaction (PCR)-positive, culture (Cx)-negative (PCR+/Cx-) patients, PCR had a 39% positive predictive value for colonization. Colonization with VRE was significantly associated with VRE infection. Among 72 patients who met decolonization criteria, 21 (29%) subsequently became recolonized. VRE recolonization was 4.3 (P = .001) and 2.0 (P = .22) times higher in patients with proportions of antibiotic days and antianaerobic antibiotic days above the median, respectively., Conclusion: Colonization is associated with clinical VRE infection and increased mortality. Despite negative perirectal cultures, re-exposure to antibiotics increases the risk of VRE recolonization.
- Published
- 2019
- Full Text
- View/download PDF
24. Investigation of a Cluster of Sphingomonas koreensis Infections.
- Author
-
Johnson RC, Deming C, Conlan S, Zellmer CJ, Michelin AV, Lee-Lin S, Thomas PJ, Park M, Weingarten RA, Less J, Dekker JP, Frank KM, Musser KA, McQuiston JR, Henderson DK, Lau AF, Palmore TN, and Segre JA
- Subjects
- Anti-Bacterial Agents pharmacology, Hospitals, Federal, Humans, Metagenomics, Microbial Sensitivity Tests, National Institutes of Health (U.S.), Retrospective Studies, Sphingomonas drug effects, Sphingomonas isolation & purification, United States, Water Supply, Whole Genome Sequencing, Cross Infection microbiology, Disease Reservoirs microbiology, Gram-Negative Bacterial Infections microbiology, Sanitary Engineering, Sphingomonas genetics
- Abstract
Background: Plumbing systems are an infrequent but known reservoir for opportunistic microbial pathogens that can infect hospitalized patients. In 2016, a cluster of clinical sphingomonas infections prompted an investigation., Methods: We performed whole-genome DNA sequencing on clinical isolates of multidrug-resistant Sphingomonas koreensis identified from 2006 through 2016 at the National Institutes of Health (NIH) Clinical Center. We cultured S. koreensis from the sinks in patient rooms and performed both whole-genome and shotgun metagenomic sequencing to identify a reservoir within the infrastructure of the hospital. These isolates were compared with clinical and environmental S. koreensis isolates obtained from other institutions., Results: The investigation showed that two isolates of S. koreensis obtained from the six patients identified in the 2016 cluster were unrelated, but four isolates shared more than 99.92% genetic similarity and were resistant to multiple antibiotic agents. Retrospective analysis of banked clinical isolates of sphingomonas from the NIH Clinical Center revealed the intermittent recovery of a clonal strain over the past decade. Unique single-nucleotide variants identified in strains of S. koreensis elucidated the existence of a reservoir in the hospital plumbing. Clinical S. koreensis isolates from other facilities were genetically distinct from the NIH isolates. Hospital remediation strategies were guided by results of microbiologic culturing and fine-scale genomic analyses., Conclusions: This genomic and epidemiologic investigation suggests that S. koreensis is an opportunistic human pathogen that both persisted in the NIH Clinical Center infrastructure across time and space and caused health care-associated infections. (Funded by the NIH Intramural Research Programs.).
- Published
- 2018
- Full Text
- View/download PDF
25. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
- Author
-
Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, and Danner RL
- Subjects
- Adolescent, Adult, Aged, Bacteremia drug therapy, Carbapenems therapeutic use, Databases, Factual, Female, Fluoroquinolones therapeutic use, Gram-Negative Bacteria drug effects, Hospitals, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Prevalence, Prognosis, Retrospective Studies, Treatment Outcome, United States epidemiology, Young Adult, Anti-Bacterial Agents therapeutic use, Bacteremia epidemiology, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections mortality
- Abstract
Background: Resistance to all first-line antibiotics necessitates the use of less effective or more toxic "reserve" agents. Gram-negative bloodstream infections (GNBSIs) harboring such difficult-to-treat resistance (DTR) may have higher mortality than phenotypes that allow for ≥1 active first-line antibiotic., Methods: The Premier Database was analyzed for inpatients with select GNBSIs. DTR was defined as intermediate/resistant in vitro to all ß-lactam categories, including carbapenems and fluoroquinolones. Prevalence and aminoglycoside resistance of DTR episodes were compared with carbapenem-resistant, extended-spectrum cephalosporin-resistant, and fluoroquinolone-resistant episodes using CDC definitions. Predictors of DTR were identified. The adjusted relative risk (aRR) of mortality was examined for DTR, CDC-defined phenotypes susceptible to ≥1 first-line agent, and graded loss of active categories., Results: Between 2009-2013, 471 (1%) of 45011 GNBSI episodes at 92 (53.2%) of 173 hospitals exhibited DTR, ranging from 0.04% for Escherichia coli to 18.4% for Acinetobacter baumannii. Among patients with DTR, 79% received parenteral aminoglycosides, tigecycline, or colistin/polymyxin-B; resistance to all aminoglycosides occurred in 33%. Predictors of DTR included urban healthcare and higher baseline illness. Crude mortality for GNBSIs with DTR was 43%; aRR was higher for DTR than for carbapenem-resistant (1.2; 95% confidence interval, 1.0-1.4; P = .02), extended-spectrum cephalosporin-resistant (1.2; 1.1-1.4; P = .001), or fluoroquinolone-resistant (1.2; 1.0-1.4; P = .008) infections. The mortality aRR increased 20% per graded loss of active first-line categories, from 3-5 to 1-2 to 0., Conclusion: Nonsusceptibility to first-line antibiotics is associated with decreased survival in GNBSIs. DTR is a simple bedside prognostic measure of treatment-limiting coresistance.
- Published
- 2018
- Full Text
- View/download PDF
26. Recommendations and barriers to vaccination in systemic lupus erythematosus.
- Author
-
Garg M, Mufti N, Palmore TN, and Hasni SA
- Subjects
- Adjuvants, Immunologic adverse effects, Adult, Clinical Studies as Topic, Humans, Immunocompromised Host, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic pathology, Practice Guidelines as Topic, Vaccination, Vaccines administration & dosage, Vaccines immunology, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated adverse effects, Lupus Erythematosus, Systemic immunology, Vaccines adverse effects
- Abstract
Patients with Systemic Lupus Erythematosus (SLE) pose a unique dilemma pertaining to immunization against common pathogens. SLE patients are usually not immunized with vaccines based on the fear of either precipitating infection in this immunosuppressed patient population (with live vaccines) or aggravating autoimmunity and hence lupus flares (with any vaccines). However, elevated vulnerability to infection makes patients with SLE precisely the population that needs protection from vaccine-preventable diseases. A summary of guidelines from the Centers for Disease Control and Prevention, professional societies, review articles and expert opinions regarding use of individual vaccines applicable to adults with SLE is presented in this review., (Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
27. Genomic Analysis of Hospital Plumbing Reveals Diverse Reservoir of Bacterial Plasmids Conferring Carbapenem Resistance.
- Author
-
Weingarten RA, Johnson RC, Conlan S, Ramsburg AM, Dekker JP, Lau AF, Khil P, Odom RT, Deming C, Park M, Thomas PJ, Henderson DK, Palmore TN, Segre JA, and Frank KM
- Subjects
- Carbapenem-Resistant Enterobacteriaceae genetics, Hospitals, Humans, Metagenomics, Prevalence, Whole Genome Sequencing, Bacterial Proteins genetics, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Plasmids analysis, Sanitary Engineering, Water Microbiology, beta-Lactamases genetics
- Abstract
The hospital environment is a potential reservoir of bacteria with plasmids conferring carbapenem resistance. Our Hospital Epidemiology Service routinely performs extensive sampling of high-touch surfaces, sinks, and other locations in the hospital. Over a 2-year period, additional sampling was conducted at a broader range of locations, including housekeeping closets, wastewater from hospital internal pipes, and external manholes. We compared these data with previously collected information from 5 years of patient clinical and surveillance isolates. Whole-genome sequencing and analysis of 108 isolates provided comprehensive characterization of bla
KPC / blaNDM -positive isolates, enabling an in-depth genetic comparison. Strikingly, despite a very low prevalence of patient infections with blaKPC -positive organisms, all samples from the intensive care unit pipe wastewater and external manholes contained carbapenemase-producing organisms (CPOs), suggesting a vast, resilient reservoir. We observed a diverse set of species and plasmids, and we noted species and susceptibility profile differences between environmental and patient populations of CPOs. However, there were plasmid backbones common to both populations, highlighting a potential environmental reservoir of mobile elements that may contribute to the spread of resistance genes. Clear associations between patient and environmental isolates were uncommon based on sequence analysis and epidemiology, suggesting reasonable infection control compliance at our institution. Nonetheless, a probable nosocomial transmission of Leclercia sp. from the housekeeping environment to a patient was detected by this extensive surveillance. These data and analyses further our understanding of CPOs in the hospital environment and are broadly relevant to the design of infection control strategies in many infrastructure settings. IMPORTANCE Carbapenemase-producing organisms (CPOs) are a global concern because of the morbidity and mortality associated with these resistant Gram-negative bacteria. Horizontal plasmid transfer spreads the resistance mechanism to new bacteria, and understanding the plasmid ecology of the hospital environment can assist in the design of control strategies to prevent nosocomial infections. A 5-year genomic and epidemiological survey was undertaken to study the CPOs in the patient-accessible environment, as well as in the plumbing system removed from the patient. This comprehensive survey revealed a vast, unappreciated reservoir of CPOs in wastewater, which was in contrast to the low positivity rate in both the patient population and the patient-accessible environment. While there were few patient-environmental isolate associations, there were plasmid backbones common to both populations. These results are relevant to all hospitals for which CPO colonization may not yet be defined through extensive surveillance.- Published
- 2018
- Full Text
- View/download PDF
28. Healthcare personnel intestinal colonization with multidrug-resistant organisms.
- Author
-
Decker BK, Lau AF, Dekker JP, Spalding CD, Sinaii N, Conlan S, Henderson DK, Segre JA, Frank KM, and Palmore TN
- Subjects
- Adult, Bacterial Infections drug therapy, Bacterial Infections microbiology, Bacterial Proteins analysis, Cross Infection microbiology, Drug Resistance, Multiple, Bacterial, Female, Humans, Male, Middle Aged, Prevalence, Risk Factors, Surveys and Questionnaires, beta-Lactamases analysis, Bacterial Infections transmission, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Carrier State microbiology, Health Personnel, Intestines microbiology, Vancomycin-Resistant Enterococci isolation & purification
- Abstract
Objectives: This study aims to assess the association between patient contact and intestinal carriage of multidrug-resistant organisms (MDRO) by sampling healthcare personnel (HCP) and staff without patient contact., Methods: For this observational study, we recruited 400 HCP who worked in our 200-bed research hospital and 400 individuals without patient contact between November 2013 and February 2015. Participants submitted two self-collected perirectal swabs and a questionnaire. Swabs were processed for multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci (VRE). Questionnaires explored occupational and personal risk factors for MDRO carriage., Results: Among 800 participants, 94.4% (755/800) submitted at least one swab, and 91.4% (731/800) also submitted questionnaires. Extended spectrum β-lactamase-producing organisms were recovered from 3.4% (26/755) of participants, and only one carbapenemase-producing organism was recovered. No VRE were detected. The potential exposure of 68.9% (250/363) of HCP who reported caring for MDRO-colonized patients did not result in a rate of MDRO carriage among HCP (4.0%; 15/379) significantly higher than that of staff without patient contact (3.2%; 12/376; p 0.55)., Conclusions: This is the largest US study of HCP intestinal MDRO carriage. The low colonization rate is probably reflective of local community background rates, suggesting that HCP intestinal colonization plays a minor role in nosocomial spread of MDROs in a non-outbreak setting., Trial Registration: clinicaltrials.gov Identifier: NCT01952158., (Published by Elsevier Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
29. Risk Factors for Viridans Group Streptococcal Bacteremia in Neutropenic and Non-neutropenic Patients: A Single Center Case-Case-Control Study.
- Author
-
Dulanto Chiang A, Sinaii N, and Palmore TN
- Abstract
Background: Viridans group streptococcal (VGS) bacteremia is common among neutropenic patients. Although VGS bacteremia occurs in non-neutropenic patients, risk factors are not well established. We conducted a case-case-control study to identify risk factors for VGS among neutropenic and non-neutropenic patients., Methods: Patients with VGS bacteremia between January 2009 and December 2014 in our 200-bed clinical research hospital were identified using microbiology records. Neutropenic and non-neutropenic patients at the time of positive culture were matched 1:1 to controls on the basis of neutrophil count (ANC), ward, and length of stay. We extracted demographic, laboratory, medication, and other clinical data from chart reviews. Data were analyzed using McNemar's test, Wilcoxon signed-rank test, and conditional logistic regression modeling., Results: Among 101 patients, 63 were neutropenic and 38 non-neutropenic at the time of VGS bacteremia. In multivariable analysis of neutropenic patients, only lower ANC predicted VGS bacteremia (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.05-0.59; P = 0.006). Recent use of vancomycin was protective (OR, 0.23; 95% CI, 0.07-0.73; P = 0.013). No clinical factors were associated with VGS in the non-neutropenic cases., Conclusions: Only lower ANC nadir increased the risk for VGS bacteremia in the neutropenic group, and vancomycin was protective. Other previously described factors (chemotherapy, radiation, oral conditions) related to neutropenia were not independently associated with VGS bacteremia. No tested clinical factors predicted infection in the non-neutropenic group. Our results suggest that VGS bacteremia should be anticipated when making antimicrobial choices in profoundly neutropenic patients, and merit further exploration in non-neutropenic patients.
- Published
- 2017
- Full Text
- View/download PDF
30. Whole-Genome Sequencing Overrules a Suspected Case of Carbapenem-Resistant Enterobacter cloacae Transmission.
- Author
-
Chen M, Conlan S, Lau AF, Dekker JP, Deming C, Henderson DK, Frank KM, Palmore TN, and Segre JA
- Subjects
- Anti-Bacterial Agents therapeutic use, Carbapenem-Resistant Enterobacteriaceae drug effects, Carbapenem-Resistant Enterobacteriaceae enzymology, Carbapenem-Resistant Enterobacteriaceae isolation & purification, DNA, Bacterial genetics, Drug Resistance, Multiple, Bacterial genetics, Enterobacter cloacae enzymology, Enterobacter cloacae isolation & purification, Enterobacteriaceae Infections diagnosis, Enterobacteriaceae Infections drug therapy, Enterobacteriaceae Infections transmission, Epidemiological Monitoring, Genes, Bacterial genetics, Humans, Intensive Care Units standards, Carbapenem-Resistant Enterobacteriaceae genetics, Enterobacter cloacae genetics, Enterobacteriaceae Infections microbiology, Genome, Bacterial, beta-Lactamases genetics
- Published
- 2017
- Full Text
- View/download PDF
31. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit.
- Author
-
Strich JR and Palmore TN
- Subjects
- Antimicrobial Stewardship, Bacterial Infections drug therapy, Bacterial Infections microbiology, Chlorhexidine administration & dosage, Cross Infection epidemiology, Cross Infection microbiology, Hand Hygiene, Humans, Intensive Care Units, United States epidemiology, Bacterial Infections prevention & control, Bacterial Infections transmission, Cross Infection prevention & control, Drug Resistance, Multiple, Bacterial, Infection Control methods
- Abstract
Infection control in the intensive care unit (ICU) has seen many advances, including rapid molecular screening tests for resistant organisms and chlorhexidine use in daily baths. Although these developments advance the cause of infection prevention, compliance with some of the basic measures remains elusive. Hand hygiene, antimicrobial stewardship, and reduction in device use remain the low-technology interventions that could have a major impact on nosocomial transmission of antimicrobial-resistant organisms. Although continued research is needed on new and old ways of preventing nosocomial infections, ICU staff must persevere in improving adherence with the measures that are known to be effective., (Published by Elsevier Inc.)
- Published
- 2017
- Full Text
- View/download PDF
32. Bilateral posterior uveitis associated with Zika virus infection.
- Author
-
Kodati S, Palmore TN, Spellman FA, Cunningham D, Weistrop B, and Sen HN
- Subjects
- Humans, Pregnancy Complications, Infectious, Uveitis, Posterior, Zika Virus, Zika Virus Infection
- Published
- 2017
- Full Text
- View/download PDF
33. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016.
- Author
-
Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, and Chiller TM
- Subjects
- Antifungal Agents therapeutic use, Candida drug effects, Candidiasis drug therapy, Communicable Diseases, Emerging, Global Health, Humans, Prognosis, Risk Factors, Time Factors, United States, Candida isolation & purification, Candidiasis diagnosis, Candidiasis microbiology, Drug Resistance, Multiple, Fungal
- Abstract
November 11, 2016/65(44);1234-1237. What is already known about this topic? Candida auris is an emerging pathogenic fungus that has been reported from at least a dozen countries on four continents during 2009-2015. The organism is difficult to identify using traditional biochemical methods, some isolates have been found to be resistant to all three major classes of antifungal medications, and C. auris has caused health care-associated outbreaks. What is added by this report? This is the first description of C. auris cases in the United States. C. auris appears to have emerged in the United States only in the last few years, and U.S. isolates are related to isolates from South America and South Asia. Evidence from U.S. case investigations suggests likely transmission of the organism occurred in health care settings. What are the implications for public health practice? It is important that U.S. laboratories accurately identify C. auris and for health care facilities to implement recommended infection control practices to prevent the spread of C. auris. Local and state health departments and CDC should be notified of possible cases of C. auris and of isolates of C. haemulonii and Candida spp. that cannot be identified after routine testing., (No claim to original US government works © 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2017
- Full Text
- View/download PDF
34. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016.
- Author
-
Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, and Chiller TM
- Subjects
- Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Candida drug effects, Candidiasis drug therapy, Communicable Diseases, Emerging, Drug Resistance, Multiple, Fungal, Fatal Outcome, Global Health, Humans, United States, Candida isolation & purification, Candidiasis diagnosis, Candidiasis microbiology
- Abstract
Candida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.
- Published
- 2016
- Full Text
- View/download PDF
35. Antimicrobial Resistance.
- Author
-
Marston HD, Dixon DM, Knisely JM, Palmore TN, and Fauci AS
- Abstract
Importance: The development of antibiotics is considered among the most important advances of modern science. Antibiotics have saved millions of lives. However, antimicrobial resistance (AMR) threatens this progress and presents significant risks to human health., Objective: To identify factors associated with AMR, the current epidemiology of important resistant organisms, and possible solutions to the AMR problem., Data Sources, Study Selection, and Data Synthesis: PubMed (2000-2016), NIH REPORTER, and ClinicalTrials.gov databases were searched for articles and entries related to AMR, focusing on epidemiology, clinical effects of AMR, discovery of novel agents to treat AMR bacterial infections, and nonpharmacological strategies to eliminate or modify AMR bacteria. In addition to articles and entries found in these databases, selected health policy reports and public health guidance documents were reviewed. Of 217 articles, databases, and reports identified, 103 were selected for review., Results: The increase in AMR has been driven by a diverse set of factors, including inappropriate antibiotic prescribing and sales, use of antibiotics outside of the health care sector, and genetic factors intrinsic to bacteria. The problem has been exacerbated by inadequate economic incentives for pharmaceutical development of new antimicrobial agents. A range of specific AMR concerns, including carbapenem- and colistin-resistant gram-negative organisms, pose a clinical challenge. Alternative approaches to address the AMR threat include new methods of antibacterial drug identification and strategies that neutralize virulence factors., Conclusions and Relevance: Antimicrobial resistance poses significant challenges for current clinical care. Modified use of antimicrobial agents and public health interventions, coupled with novel antimicrobial strategies, may help mitigate the effect of multidrug-resistant organisms in the future.
- Published
- 2016
- Full Text
- View/download PDF
36. Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010-2013.
- Author
-
Bok K, Prevots DR, Binder AM, Parra GI, Strollo S, Fahle GA, Behrle-Yardley A, Johnson JA, Levenson EA, Sosnovtsev SV, Holland SM, Palmore TN, and Green KY
- Abstract
Background. Noroviruses are a major cause of infectious gastroenteritis worldwide, and viruses can establish persistent infection in immunocompromised individuals. Risk factors and transmission in this population are not fully understood. Methods. From 2010 through 2013, we conducted a retrospective review among immunocompromised patients (n = 268) enrolled in research studies at the National Institutes of Health Clinical Center and identified a subset of norovirus-positive patients (n = 18) who provided stool specimens for norovirus genotyping analysis. Results. Norovirus genome was identified by reverse-transcription quantitative polymerase chain reaction in stools of 35 (13%) of the 268 immunocompromised patients tested, and infection prevalence was 21% (11 of 53) in persons with primary immune deficiencies and 12% (20 of 166) among persons with solid tumors or hematologic malignancies. Among 18 patients with norovirus genotyping information, norovirus GII.4 was the most prevalent genotype (14 of 18, 78%). Persistent norovirus infection (≥6 months) was documented in 8 of 18 (44%) individuals. Phylogenetic analysis of the GII.4 capsid protein sequences identified at least 5 now-displaced GII.4 variant lineages, with no evidence of their nosocomial transmission in the Clinical Center. Conclusions. Norovirus was a leading enteric pathogen identified in this immunocompromised population. Both acute and chronic norovirus infections were observed, and these were likely community-acquired. Continued investigation will further define the role of noroviruses in these patients and inform efforts toward prevention and treatment.
- Published
- 2016
- Full Text
- View/download PDF
37. Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report.
- Author
-
Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, Bishop RJ, Childs RW, Arai AE, Palmore TN, Lane HC, Fauci AS, and Davey RT
- Subjects
- Adult, Brain diagnostic imaging, Brain virology, Hemorrhagic Fever, Ebola therapy, Humans, Magnetic Resonance Imaging, Male, Meningoencephalitis diagnostic imaging, Meningoencephalitis therapy, Multiple Organ Failure therapy, Hemorrhagic Fever, Ebola complications, Meningoencephalitis virology, Multiple Organ Failure virology
- Published
- 2016
- Full Text
- View/download PDF
38. Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.
- Author
-
Wong KK, Davey RT Jr, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, Palmore TN, Rogers S, Smith PW, Suffredini AF, Wolcott M, Ströher U, and Uyeki TM
- Subjects
- Adult, Africa, Western, Female, Hemorrhagic Fever, Ebola diagnosis, Hemorrhagic Fever, Ebola virology, Humans, Male, Middle Aged, Post-Exposure Prophylaxis, Retrospective Studies, United States, Ebolavirus physiology, Hemorrhagic Fever, Ebola prevention & control, Occupational Exposure
- Abstract
From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease., (Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.)
- Published
- 2016
- Full Text
- View/download PDF
39. Complete Genome Sequence of a Klebsiella pneumoniae Strain Carrying blaNDM-1 on a Multidrug Resistance Plasmid.
- Author
-
Conlan S, Lau AF, Palmore TN, Frank KM, and Segre JA
- Abstract
Here, we report the genome sequence of a blaNDM-1-positive Klebsiella pneumoniae AATZP isolate cultured from a perirectal surveillance swab collected upon admission of a patient to the NIH Clinical Center in 2014. Genome sequencing of this isolate revealed three plasmids, including one carrying the blaNDM-1 gene encoding resistance to carbapenems., (Copyright © 2016 Conlan et al.)
- Published
- 2016
- Full Text
- View/download PDF
40. Plasmid Dynamics in KPC-Positive Klebsiella pneumoniae during Long-Term Patient Colonization.
- Author
-
Conlan S, Park M, Deming C, Thomas PJ, Young AC, Coleman H, Sison C, Weingarten RA, Lau AF, Dekker JP, Palmore TN, Frank KM, and Segre JA
- Subjects
- Bacterial Proteins biosynthesis, Cross Infection, DNA, Bacterial genetics, Disease Outbreaks, Electrophoresis, Gel, Pulsed-Field, Escherichia coli, Female, Gene Transfer, Horizontal, High-Throughput Nucleotide Sequencing, Humans, Klebsiella Infections transmission, Klebsiella pneumoniae enzymology, Klebsiella pneumoniae isolation & purification, Male, Time Factors, beta-Lactamases biosynthesis, Bacterial Proteins genetics, Drug Resistance, Multiple, Bacterial genetics, Genome, Bacterial, Klebsiella Infections microbiology, Klebsiella pneumoniae genetics, Klebsiella pneumoniae growth & development, Plasmids, beta-Lactamases genetics
- Abstract
Unlabelled: Carbapenem-resistant Klebsiella pneumoniae strains are formidable hospital pathogens that pose a serious threat to patients around the globe due to a rising incidence in health care facilities, high mortality rates associated with infection, and potential to spread antibiotic resistance to other bacterial species, such as Escherichia coli Over 6 months in 2011, 17 patients at the National Institutes of Health (NIH) Clinical Center became colonized with a highly virulent, transmissible carbapenem-resistant strain of K. pneumoniae Our real-time genomic sequencing tracked patient-to-patient routes of transmission and informed epidemiologists' actions to monitor and control this outbreak. Two of these patients remained colonized with carbapenemase-producing organisms for at least 2 to 4 years, providing the opportunity to undertake a focused genomic study of long-term colonization with antibiotic-resistant bacteria. Whole-genome sequencing studies shed light on the underlying complex microbial colonization, including mixed or evolving bacterial populations and gain or loss of plasmids. Isolates from NIH patient 15 showed complex plasmid rearrangements, leaving the chromosome and the blaKPC-carrying plasmid intact but rearranging the two other plasmids of this outbreak strain. NIH patient 16 has shown continuous colonization with blaKPC-positive organisms across multiple time points spanning 2011 to 2015. Genomic studies defined a complex pattern of succession and plasmid transmission across two different K. pneumoniae sequence types and an E. coli isolate. These findings demonstrate the utility of genomic methods for understanding strain succession, genome plasticity, and long-term carriage of antibiotic-resistant organisms., Importance: In 2011, the NIH Clinical Center had a nosocomial outbreak involving 19 patients who became colonized or infected with blaKPC-positive Klebsiella pneumoniae Patients who have intestinal colonization with blaKPC-positive K. pneumoniae are at risk for developing infections that are difficult or nearly impossible to treat with existing antibiotic options. Two of those patients remained colonized with blaKPC-positive Klebsiella pneumoniae for over a year, leading to the initiation of a detailed genomic analysis exploring mixed colonization, plasmid recombination, and plasmid diversification. Whole-genome sequence analysis identified a variety of changes, both subtle and large, in the blaKPC-positive organisms. Long-term colonization of patients with blaKPC-positive Klebsiella pneumoniae creates new opportunities for horizontal gene transfer of plasmids encoding antibiotic resistance genes and poses complications for the delivery of health care., (Copyright © 2016 Conlan et al.)
- Published
- 2016
- Full Text
- View/download PDF
41. Detection and Whole-Genome Sequencing of Carbapenemase-Producing Aeromonas hydrophila Isolates from Routine Perirectal Surveillance Culture.
- Author
-
Hughes HY, Conlan SP, Lau AF, Dekker JP, Michelin AV, Youn JH, Henderson DK, Frank KM, Segre JA, and Palmore TN
- Subjects
- Adult, Aeromonas hydrophila classification, Aeromonas hydrophila isolation & purification, Epidemiological Monitoring, Feces microbiology, Genetic Variation, Genotype, Humans, Molecular Epidemiology, Aeromonas hydrophila enzymology, Aeromonas hydrophila genetics, Anal Canal microbiology, Bacterial Proteins genetics, Genome, Bacterial, Sequence Analysis, DNA, beta-Lactamases genetics
- Abstract
Perirectal surveillance cultures and a stool culture grew Aeromonas species from three patients over a 6-week period and were without epidemiological links. Detection of the blaKPC-2 gene in one isolate prompted inclusion of non-Enterobacteriaceae in our surveillance culture workup. Whole-genome sequencing confirmed that the isolates were unrelated and provided data for Aeromonas reference genomes., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
42. Critical Care Medicine After the 2014-2015 Ebola Outbreak: Are We Ready If It Happens Again?
- Author
-
Chertow DS, Palmore TN, and Masur H
- Subjects
- Communicable Disease Control methods, Critical Care methods, Hemorrhagic Fever, Ebola prevention & control, Humans, Communicable Diseases, Emerging prevention & control, Disaster Planning, Disease Outbreaks prevention & control
- Published
- 2016
- Full Text
- View/download PDF
43. Draft Genome Sequence of a Klebsiella pneumoniae Carbapenemase-Positive Sequence Type 111 Pseudomonas aeruginosa Strain.
- Author
-
Dotson GA, Dekker JP, Palmore TN, Segre JA, and Conlan S
- Abstract
Here, we report the draft genome sequence of a sequence type 111 Pseudomonas aeruginosa strain isolated in 2014 from a patient at the NIH Clinical Center. This P. aeruginosa strain exhibits pan-drug resistance and harbors the blaKPC-2 gene, encoding the Klebsiella pneumoniae carbapenemase enzyme, on a plasmid., (Copyright © 2016 Dotson et al.)
- Published
- 2016
- Full Text
- View/download PDF
44. Adequacy of Duodenoscope Reprocessing Methods as Reported by Infectious Disease Physicians.
- Author
-
Beekmann SE, Palmore TN, Polgreen PM, and Bennett JE
- Subjects
- Communicable Diseases, Disinfection methods, Equipment Reuse, Ethylene Oxide administration & dosage, Health Care Surveys, Humans, Physicians, Cross Infection prevention & control, Duodenoscopes microbiology, Equipment Contamination
- Published
- 2016
- Full Text
- View/download PDF
45. Intensifying the Focus on the Contribution of the Inanimate Environment to Health Care-Associated Infections.
- Author
-
Palmore TN and Henderson DK
- Subjects
- Humans, Cross Infection prevention & control, Disinfection methods, Patients' Rooms
- Published
- 2015
- Full Text
- View/download PDF
46. Isolation precautions for visitors.
- Author
-
Munoz-Price LS, Banach DB, Bearman G, Gould JM, Leekha S, Morgan DJ, Palmore TN, Rupp ME, Weber DJ, and Wiemken TL
- Subjects
- Hand Hygiene, Hospitals standards, Humans, Masks, Disease Outbreaks prevention & control, Disease Transmission, Infectious prevention & control, Patient Isolation methods, Visitors to Patients
- Published
- 2015
- Full Text
- View/download PDF
47. Challenges in managing patients who have suspected or confirmed Ebola virus infection at the National Institutes of Health.
- Author
-
Palmore TN, Barrett K, Michelin A, Ramsburg A, Lee LM, Davey RT, and Henderson DK
- Subjects
- Anxiety physiopathology, Disease Management, Humans, Medical Waste Disposal methods, National Institutes of Health (U.S.), Safety Management methods, Safety Management organization & administration, United States, Attitude of Health Personnel, Hemorrhagic Fever, Ebola psychology, Hemorrhagic Fever, Ebola therapy, Occupational Exposure prevention & control
- Published
- 2015
- Full Text
- View/download PDF
48. Radiology preparedness in ebola virus disease: guidelines and challenges for disinfection of medical imaging equipment for the protection of staff and patients.
- Author
-
Mollura DJ, Palmore TN, Folio LR, and Bluemke DA
- Subjects
- Centers for Disease Control and Prevention, U.S., Humans, Practice Guidelines as Topic, Radiography instrumentation, United States, Cross Infection prevention & control, Cross Infection transmission, Diagnostic Imaging instrumentation, Disinfection standards, Equipment Contamination prevention & control, Health Personnel, Hemorrhagic Fever, Ebola prevention & control, Hemorrhagic Fever, Ebola transmission, Occupational Diseases prevention & control, Radiology Department, Hospital standards
- Abstract
The overlap of early Ebola virus disease (EVD) symptoms (eg, fever, headache, abdominal pain, diarrhea, emesis, and fatigue) with symptoms of other more common travel-related diseases (eg, malaria, typhoid fever, pneumonia, and meningococcemia) may result in delayed diagnosis of EVD before isolation of infected patients. Radiology departments should consider policies for and approaches to decontamination of expensive and potentially easily damaged radiology equipment. In addition, the protection of radiology personnel must be considered during the work-up phase of undiagnosed EVD patients presenting to emergency departments. The purpose of this article is to consider the effect of EVD on radiology departments and imaging equipment, with particular consideration of guidelines currently available from the Centers for Disease Control and Prevention that may be applicable to radiology., ((©) RSNA, 2015.)
- Published
- 2015
- Full Text
- View/download PDF
49. Hospital water and opportunities for infection prevention.
- Author
-
Decker BK and Palmore TN
- Abstract
Nosocomial waterborne pathogens may reach patients through several modes of transmission. Colonization of healthcare facility waterworks can occur in the proximal infrastructure, in the distal water outlets, or both. Infections with waterborne organisms such as Legionella, mycobacteria, Pseudomonas, and others cause significant morbidity and mortality, particularly in immunocompromised patients. Hospitals should have prospective water safety plans that include preventive measures, as prevention is preferable to remediation of contaminated hospital water distribution systems. Whole-genome sequencing may provide more informative epidemiologic data to link patient infections with hospital water isolates.
- Published
- 2014
- Full Text
- View/download PDF
50. Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae.
- Author
-
Conlan S, Thomas PJ, Deming C, Park M, Lau AF, Dekker JP, Snitkin ES, Clark TA, Luong K, Song Y, Tsai YC, Boitano M, Dayal J, Brooks SY, Schmidt B, Young AC, Thomas JW, Bouffard GG, Blakesley RW, Mullikin JC, Korlach J, Henderson DK, Frank KM, Palmore TN, and Segre JA
- Subjects
- Enterobacteriaceae classification, Enterobacteriaceae genetics, Hospitals, Public, Humans, National Institutes of Health (U.S.), Population Surveillance, Real-Time Polymerase Chain Reaction, United States, Bacterial Proteins biosynthesis, Cross Infection, Enterobacteriaceae enzymology, Plasmids, beta-Lactamases biosynthesis
- Abstract
Public health officials have raised concerns that plasmid transfer between Enterobacteriaceae species may spread resistance to carbapenems, an antibiotic class of last resort, thereby rendering common health care-associated infections nearly impossible to treat. To determine the diversity of carbapenemase-encoding plasmids and assess their mobility among bacterial species, we performed comprehensive surveillance and genomic sequencing of carbapenem-resistant Enterobacteriaceae in the National Institutes of Health (NIH) Clinical Center patient population and hospital environment. We isolated a repertoire of carbapenemase-encoding Enterobacteriaceae, including multiple strains of Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter cloacae, Citrobacter freundii, and Pantoea species. Long-read genome sequencing with full end-to-end assembly revealed that these organisms carry the carbapenem resistance genes on a wide array of plasmids. K. pneumoniae and E. cloacae isolated simultaneously from a single patient harbored two different carbapenemase-encoding plasmids, indicating that plasmid transfer between organisms was unlikely within this patient. We did, however, find evidence of horizontal transfer of carbapenemase-encoding plasmids between K. pneumoniae, E. cloacae, and C. freundii in the hospital environment. Our data, including full plasmid identification, challenge assumptions about horizontal gene transfer events within patients and identify possible connections between patients and the hospital environment. In addition, we identified a new carbapenemase-encoding plasmid of potentially high clinical impact carried by K. pneumoniae, E. coli, E. cloacae, and Pantoea species, in unrelated patients and in the hospital environment., (Copyright © 2014, American Association for the Advancement of Science.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.